ADELAJA A AKİNLOLU, TEMİTOPE OMOHİMORİA, ADEOYE OYEWOPO, RİSİKAT E KADİR, MUBARAK O AMEEN, OLİVİA AHİALAKA, SİMİSOLA OGUNFOWORA
Acta Pharmaceutica Sciencia - 2022;60(1):65-84
This study evaluated anticancer potentials of Morinda lucida (ML) and Annona muricata (AM) on Ki67 and Multi-drug resistance1 (MDR1) concentrations in livers of rats in Sodium arsenite (SA)-induced hepato-toxicity. 60 adult female rats were randomly divided into 12 groups (n= 5). Groups 1 and 2 received physiological saline and 10mg/kg bodyweight of SA respectively. Groups 3-6 received SA followed by treatments with ML and AM doses. Groups 7-10 received extracts only. Groups 11-12 received co-administrations of SA with extracts. Drugs/extracts were administered orally. Experimental procedure was 5 weeks. Consequently, Liver histo-pathology and ELISA concentrations of Ki67 and MDR1 were evaluated. Data were statistically analyzed (P?0.05). Results showed decreased levels of Ki67 (Groups 11-12) and MDR1 (Groups 3-4 and 11) compared with Group 2, indicating that ML ameliorated SA-induced hyperplasia and drug resistance, while AM ameliorated SA-induced hyperplasia. Therefore, ML possesses anti-proliferation and anti-drug resistance potentials, while AM possesses anti-proliferation potentials.
